ReviewWorld journal of gastroenterology2014
Optimum chemotherapy in the management of metastatic pancreatic cancer.
Review in World journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- The benefits of liver resection for non-colorectal, non-neuroendocrine liver metastases: a systematic review.Langenbeck's archives of surgery · 2014Pooled it
- Article
- Multiscale anisotropy analysis of second-harmonic generation collagen imaging of human pancreatic cancer.Frontiers in oncology · 2022Article
- Conversion Therapy for Advanced Pancreatic Cancer: The Case Series and Literature Review.Frontiers in pharmacology · 2020Article
- EIF5A regulates proliferation and chemoresistance in pancreatic cancer through the sHH signalling pathway.Journal of cellular and molecular medicine · 2019Article
- Irreversible electroporation combined with chemotherapy for unresectable pancreatic carcinoma: a prospective cohort study.OncoTargets and therapy · 2019Article
- Photothermal Effects of Reduced Graphene Oxide on Pancreatic Cancer.Technology in cancer research & treatment · 2018Article
- Small bowel metastasis from pancreatic cancer in a long-term survival patient with synchronous advanced malignant pleural mesothelioma: A case report and literature review.Oncology letters · 2016Article
- Irreversible Electroporation.Seminars in interventional radiology · 2015Review
- Targeting Pancreatic Cancer Metastasis by Inhibition of Vav1, a Driver of Tumor Cell Invasion.Cancer research · 2015Article
- Systemic therapy in stage IV pancreatic cancer: a population-based analysis using the National Cancer Data Base.Therapeutic advances in medical oncology · 2015Article
- Molecular Profiling-Selected Therapy for Treatment of Advanced Pancreaticobiliary Cancer: A Retrospective Multicenter Study.BioMed research international · 2015Article
- Curaxin CBL0137 eradicates drug resistant cancer stem cells and potentiates efficacy of gemcitabine in preclinical models of pancreatic cancer.Oncotarget · 2014Article
- Diabetes, pancreatic cancer, and metformin therapy.Frontiers in physiology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer is one of the most devastating solid tumors, and it remains one of the most difficult to treat. The treatment of metastatic pancreatic cancer (MPC) is systemic, based on chemotherapy or best supportive care, depending on the performance status of the patient. Two chemotherapeutical regimens have produced substantial benefits in the treatment of MPC: gemcitabine in 1997; and FOLFIRIONOX in 2011. FOLFIRINOX improved the natural history of MPC, with overall survival (OS) of 11.1 mo. Nab-paclitaxel associated with gemcitabine is a newly approved regimen for MPC, with a median OS of 8.6 mo. Despite multiple trials, this targeted therapy was not efficient in the treatment of MPC. Many new molecules targeting the proliferation and survival pathways, immune response, oncofetal signaling and the epigenetic changes are currently undergoing phase I and II trials for the treatment of MPC, with many promising results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.